RLAY Relay Therapeutics, Inc.
Healthcare$14.17+4.73%ClosedMarket Cap: $2.71B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.79
P/S
242.78
EV/EBITDA
-8.30
DCF Value
$-0.75
FCF Yield
-8.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.7%
Operating Margin
-2776.6%
Net Margin
-2554.1%
ROE
-43.9%
ROA
-39.0%
ROIC
-44.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.0M | 83.2% | $-78.6M | $-73.3M | $— | — |
| Q4 null | $7.0M | 91.4% | $-60.6M | $-54.9M | $— | — |
| FY null | $15.4M | 76.8% | $-302.7M | $-276.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-80.4M | $-74.1M | $— | — |
| Q2 null | $677.0K | 100.0% | $-76.8M | $-70.4M | $— | — |
| Q1 null | $7.7M | 100.0% | $-84.9M | $-77.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-85.0M | $-76.0M | $— | — |
| FY null | $10.0M | 100.0% | $-372.5M | $-337.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-96.4M | $-88.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-100.8M | $-92.2M | $— | — |
| Q1 null | $10.0M | 100.0% | $-90.4M | $-81.4M | $— | — |
| Q4 2023 | $-1.0K | 100.0% | $-92.2M | $-83.5M | $-0.68 | — |